Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma A549 cells

Toxicological Sciences

Volumn 91, Issue 1, 2006, Pages 132-139

  Zhu, Huijun ^a,b   Gooderham, Nigel J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

A549 cells; ATM; Cryptolepine; DNA PK; p21Cip1 WAF1; p53

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; CRYPTOLEPINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; DNA DEPENDENT PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOLECULAR DYNAMICS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ALKALOIDS; ANDROSTADIENES; APOPTOSIS; CAFFEINE; CELL CYCLE; CELL LINE, TUMOR; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; INDOLES; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; MORPHOLINES; QUINOLINES;

ATAXIA TELANGIECTASIA;

EID: 33645816979     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj146     Document Type: Article

References (49)

1. Abraham, R. T. (2004). PI 3-kinase related kinases: 'Big' players in stress-induced signaling pathways. DNA Repair (Amst) 3, 883-887.
2. Aguero, M. F., Facchinetti, M. M., Sheleg, Z., and Senderowicz, A. M. (2005). Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclindependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 65, 3364-3373.
3. Aliouat-Denis, C. M., Dendouga, N., Van den Wyngaert, I., Goehlmann, H., Steller, U., van de Weyer, I., Van Slycken, N., Andries, L., Kass, S., Luyten, W., et al. (2005). p53-Independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol. Cancer Res. 3, 627-634.
4. Ansah, C., and Gooderham, N. J. (2002). The popular herbal antimalarial, extract of Cryptolepis sanguinolenta, is potently cytotoxic. Toxicol. Sci. 70, 245-251.
5. Ansah, C., Khan, A., and Gooderham, N. J. (2005). In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepine. Toxicology 208, 141-147.
6. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677.
7. Bonjean, K., De Pauw-Gillet, M. C., Defresne, M. P., Colson, P., Houssier, C., Dassonneville, L., Bailly, C., Greimers, R., Wright, C., Quetin-Leclercq, J., et al. (1998). The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry 37, 5136-5146.
8. Bourdon, J. C., Deguin-Chambon, V., Lelong, J. C., Dessen, P., May, P., Debuire, B., and May, E. (1997). Further characterisation of the p53 responsive element - Identification of new candidate genes for transactivation by p53. Oncogene 14, 85-94.
9. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679.
10. Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., et al. (1999). Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047-4054.
11. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374, 386-388.
12. Critchlow, S. E., Bowater, R. P., and Jackson, S. P. (1997). Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr. Biol. 7, 588-598.
13. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M. A., Lassota, P., and Traganos, F. (1992). Features of apoptotic cells measured by flow cytometry. Cytometry 13, 795-808.
14. Dassonneville, L., Lansiaux, A., Wattelet, A., Wattez, N., Mahieu, C., Van Miert, S., Pieters, L., and Bailly, C. (2000). Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: Relation to drug-induced apoptosis. Eur. J. Pharmacol. 409, 9-18.
15. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
16. Erster, S., Mihara, M., Kim, R. H., Petrenko, O., and Moll, U. M. (2004). In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell. Biol. 24, 6728-6741.
17. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
18. Furnari, B., Rhind, N., and Russell, P. (1997). Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277, 1495-1497.
19. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. (1991). Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. U.S.A. 88, 9979-9983.
20. Jhappan, C., Yusufzai, T. M., Anderson, S., Anver, M. R., and Merlino, G. (2000). The p53 response to DNA damage in vivo is independent of DNA-dependent protein kinase. Mol. Cell. Biol. 20, 4075-4083.
21. Johnson, A., and O'Donnell, M. (2005). Cellular DNA replicases: Components and dynamics at the replication fork. Annu. Rev. Biochem. 74, 283-315.
22. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. (1993). Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365, 349-352.
23. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. (1993). Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7, 331-342.
24. Kumagai, A., and Dunphy, W. G. (1999). Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. Genes Dev. 13, 1067-1072.
25. Li, J., and Stern, D. F. (2005). Regulation of CHK2 by DNA-dependent protein kinase. J. Biol. Chem. 280, 12041-12050.
26. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448-1459.
27. Lopez-Girona, A., Furnari, B., Mondesert, O., and Russell, P. (1999). Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397, 172-175.
28. Ludes-Meyers, J. H., Subler,M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., and Deb, S. (1996). Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16, 6009-6019.
29. Luo, Y., Hurwitz, J., and Massague, J. (1995). Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375, 159-161.
30. Majka, J., and Burgers, P. M. (2004). The PCNA-RFC families of DNA clamps and clamp loaders. Prog. Nucleic Acid Res. Mol. Biol. 78, 227-260.
31. Margueron, R., Licznar, A., Lazennec, G., Vignon, F., and Cavailles, V. (2003). Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J. Endocrinol. 179, 41-53.
32. Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., and Elledge, S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 97, 10389-10394.
33. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590.
34. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271-279.
35. Nurse, P. (1990). Universal control mechanism regulating onset of M-phase. Nature 344, 503-508.
36. Park, J. S., Qiao, L., Gilfor, D., Yang, M. Y., Hylemon, P. B., Benz, C., Darlington, G., Firestone, G., Fisher, P. B., and Dent, P. (2000). A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. Mol. Biol. Cell 11, 2915-2932.
37. Ren, S., Gao, C., Zhang, L., Koike, K., and Tsuchida, N. (2003). PI3K inhibitors changed the p53-induced response of Saos-2 cells from growth arrest to apoptosis. Biochem. Biophys. Res. Commun. 308, 120-125.
38. Sanchez, Y.,Wong, C., Thoma, R. S., Richman, R.,Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997). Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501.
39. Schuler, M., and Green, D. R. (2005). Transcription, apoptosis and p53: Catch-22. Trends Genet. 21, 182-187.
40. Scott, M. T., Morrice, N., and Ball, K. L. (2000). Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding. J. Biol. Chem. 275, 11529-11537.
41. Sheikh, M. S., Li, X. S., Chen, J. C., Shao, Z. M., Ordonez, J. V., and Fontana, J. A. (1994). Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 9, 3407-3415.
42. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
43. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. (1999). A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13, 152-157.
44. Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C., and Durkacz, B. W. (2003). Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008-6015.
45. Willmore, E., de Caux, S., Sunter, N. J., Tilby, M. J., Jackson, G. H., Austin, C. A., and Durkacz, B. W. (2004). A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103, 4659-4665.
46. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
47. Yam, C. H., Fung, T. K., and Poon, R. Y. (2002). Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci. 59, 1317-1326.
48. Yee, K. S., and Vousden, K. H. (2005). Complicating the complexity of p53. Carcinogenesis 26, 1317-1322.
49. Zhu, H., Boobis, A. R., and Gooderham, N. J. (2000). The food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine activates Sphase checkpoint and apoptosis, and induces gene mutation in human lymphoblastoid TK6 cells. Cancer Res. 60, 1283-1289.